Autorisation d’accès précoce refusée à la spécialité QALSODY (tofersen) dans l’indication « traitement des adultes atteints de sclérose latérale amyotrophique (SLA) associée à une mutation du gène superoxyde dismutase 1 (SOD1) ».
See also
HAS opinions and decisions
22/10/2024
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
EAvFFavF0DHxs02E
